Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106379 · ClinicalTrials.gov registry record · Phase 4
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
A Phase 4 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT00106379 is a Phase 4 study that has completed, run by Gilead Sciences. The registered enrollment target is 52 participants.
The verdict
NCT00106379, a Phase 4 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to provide long-term clinical safety and efficacy data for tenofovir disoproxil fumarate and emtricitabine in HIV-infected patients experiencing various degrees of renal impairment.
Interventions
- DRUG Truvada (tenofovir DF + emtricitabine)
- DRUG Emtriva (emtricitabine)
- DRUG Viread (tenofovir DF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106379
The ClinicalTrials.gov registry entry for NCT00106379 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Truvada (tenofovir DF + emtricitabine) is the first listed.
NCT00106379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106379 about?
NCT00106379 is a clinical study titled "Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients". The purpose of this study is to provide long-term clinical safety and efficacy data for tenofovir disoproxil fumarate and emtricitabine in HIV-infected patients experiencing various degrees of renal impairment.
What is the current status of trial NCT00106379?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2004-10. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00106379?
The interventions under investigation include: Truvada (tenofovir DF + emtricitabine) (DRUG), Emtriva (emtricitabine) (DRUG), Viread (tenofovir DF) (DRUG).
Who is sponsoring clinical trial NCT00106379?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.